(S)-Glutamic acid Clinical Trials

Size	Price	Qty
25mg	USD 97
1g	USD 970

Clinical Trials

Multiple clinical trials evaluate therapeutic, diagnostic, and metabolic interventions involving (S)-Glutamic acid across Early Phase 1 through Phase 4 studies. Investigated indications include Parkinson's disease, Type 1 diabetes mellitus, acute aortic syndrome, metabolic associated fatty liver disease, vertigo, and gynecologic malignancies, with recruitment statuses spanning completed, recruiting, active, not yet recruiting, and terminated. Academic medical centers, government institutes, and biotechnology companies—including Nanjing Medical University, the National Institute of Diabetes and Digestive and Kidney Diseases, Diamyd Medical AB, and MeiraGTx, LLC—sponsor these diverse research efforts.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05894343	ACTIVE_NOT_RECRUITING	Parkinson's Disease	MeiraGTx, LLC	2023-05-19	PHASE1; PHASE2
NCT05018585	TERMINATED	Type 1 Diabetes Mellitus	Diamyd Medical AB	2022-05-19	PHASE3
NCT05339529	RECRUITING	Acute Aortic Syndrome; Aortic Dissection Type a	Nanjing Medical University	2022-07-01
NCT05603312	COMPLETED	Parkinson's Disease	MeiraGTx, LLC	2022-10-05	PHASE1; PHASE2
NCT05221892	COMPLETED	Vertigo	Fundação Educacional Serra dos Órgãos	2021-11-22	PHASE4
NCT04262479	COMPLETED	Latent Autoimmune Diabetes in Adults	Norwegian University of Science and Technology	2020-03-02	PHASE2
NCT02002130	COMPLETED	Type I Diabetes	University of Alabama at Birmingham	2015-01	PHASE1
NCT02872519	WITHDRAWN	Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer	Vanderbilt-Ingram Cancer Center	2018-06	EARLY_PHASE1
NCT01826045	COMPLETED	Cervical Intraepithelial Neoplasia	BioLeaders Corporation	2013-06	PHASE2
NCT00369564	COMPLETED	Kidney Cancer; Leukemia; Lymphoma; Neurotoxicity; Peripheral Neuropathy; Sarcoma	University of South Florida	2007-05	PHASE3
NCT00529399	COMPLETED	Type 1 Diabetes Mellitus	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	2009-02	PHASE2
NCT00980408	COMPLETED	Healthy Individuals	University Hospital, Bonn	2008-06
NCT00643890	TERMINATED	Parkinson's Disease	Neurologix, Inc.	2008-08	PHASE2
NCT00000768	COMPLETED	Colitis; HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)		PHASE1

(data from https://clinicaltrials.gov, updated on 2026-09-01)

Check the (S)-Glutamic acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

(S)-Glutamic acid functions as an endogenous, non-selective agonist that binds directly to ionotropic and metabotropic glutamate receptors, triggering cation influx and activating downstream intracellular signaling cascades essential for excitatory neurotransmission and metabolic homeostasis. This agonist-mediated stimulation modulates synaptic plasticity and cellular excitability, providing therapeutic relevance in clinical trial investigations targeting central nervous system disorders such as Parkinson's disease as well as metabolic conditions like Type 1 diabetes mellitus.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).